Improvement effect of fatty liver and influence of periodontitis by Amazake intake

Improvement effect of fatty liver and influence of periodontitis by Amazake intake - Improvement effect of fatty liver by Amazake

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030597

Enrollment

Registered

2017-12-27

Start date

2017-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver

Interventions

Each patient drinks Amazake (100g, 112 kcal) once a day for 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fatty liver patients who have liver abnormality such as AST value and ALT value

Exclusion criteria

Exclusion criteria: 1. Patients who consume Amazake for over one month 2. Complicated patients with other liver diseases such as HCV and/or HBV-infected hepatitis 3. Diabetic patients receiving insulin therapy 4. Hepatic encephalopathy, ascites, liver cancer 5. Renal failure

Design outcomes

Primary

Measure	Time frame
Changes in liver function values and periodontal disease bacteria	—

Countries

Japan

Contacts

Public ContactYumiko Nagao

Saga University Department of Organ System Interactions and Information, Faculty of Medicine

nagaoyu@cc.saga-u.ac.jp0952-34-2516

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026